VERTEX PHARMACEUTICALS INC (VX1.DE) Stock Fundamental Analysis
Europe - FRA:VX1 - US92532F1003 - Common Stock
369.15 EUR
-0.6 (-0.16%)
We assign a fundamental rating of 6 out of 10 to VX1. VX1 was compared to 77 industry peers in the Biotechnology industry. VX1 gets an excellent profitability rating and is at the same time showing great financial health properties. VX1 is growing strongly while it is still valued neutral. This is a good combination! These ratings could make VX1 a good candidate for growth and quality investing.
1. Profitability
1.1 Basic Checks
In the past year VX1 was profitable.
In the past year VX1 had a positive cash flow from operations.
VX1 had positive earnings in 4 of the past 5 years.
VX1 had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
VX1 has a Return On Assets of 15.13%. This is amongst the best in the industry. VX1 outperforms 88.16% of its industry peers.
VX1 has a better Return On Equity (21.18%) than 90.79% of its industry peers.
Looking at the Return On Invested Capital, with a value of 15.66%, VX1 belongs to the top of the industry, outperforming 92.11% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for VX1 is above the industry average of 13.32%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 15.13% | ||
| ROE | 21.18% | ||
| ROIC | 15.66% |
ROA(3y)10.62%
ROA(5y)14.47%
ROE(3y)13.73%
ROE(5y)19.12%
ROIC(3y)17.53%
ROIC(5y)18.06%
1.3 Margins
VX1's Profit Margin of 31.86% is amongst the best of the industry. VX1 outperforms 89.47% of its industry peers.
VX1 has a Operating Margin of 38.77%. This is amongst the best in the industry. VX1 outperforms 93.42% of its industry peers.
VX1's Operating Margin has improved in the last couple of years.
VX1 has a better Gross Margin (86.11%) than 78.95% of its industry peers.
VX1's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 38.77% | ||
| PM (TTM) | 31.86% | ||
| GM | 86.11% |
OM growth 3Y2.79%
OM growth 5Y6.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y-0.17%
2. Health
2.1 Basic Checks
VX1 has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
VX1 has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, VX1 has less shares outstanding
The debt/assets ratio for VX1 has been reduced compared to a year ago.
2.2 Solvency
There is no outstanding debt for VX1. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | N/A |
ROIC/WACC1.67
WACC9.37%
2.3 Liquidity
VX1 has a Current Ratio of 2.52. This indicates that VX1 is financially healthy and has no problem in meeting its short term obligations.
VX1 has a Current ratio (2.52) which is in line with its industry peers.
VX1 has a Quick Ratio of 2.16. This indicates that VX1 is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.16, VX1 is in line with its industry, outperforming 55.26% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.52 | ||
| Quick Ratio | 2.16 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 7966.67% over the past year.
Measured over the past years, VX1 shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -44.14% on average per year.
Looking at the last year, VX1 shows a quite strong growth in Revenue. The Revenue has grown by 10.46% in the last year.
VX1 shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 21.50% yearly.
EPS 1Y (TTM)7966.67%
EPS 3Y-71.86%
EPS 5Y-44.14%
EPS Q2Q%135.23%
Revenue 1Y (TTM)10.46%
Revenue growth 3Y13.31%
Revenue growth 5Y21.5%
Sales Q2Q%12.06%
3.2 Future
Based on estimates for the next years, VX1 will show a very strong growth in Earnings Per Share. The EPS will grow by 150.50% on average per year.
Based on estimates for the next years, VX1 will show a quite strong growth in Revenue. The Revenue will grow by 9.58% on average per year.
EPS Next Y6246.89%
EPS Next 2Y746.68%
EPS Next 3Y328.73%
EPS Next 5Y150.5%
Revenue Next Year10.06%
Revenue Next 2Y9.8%
Revenue Next 3Y9.54%
Revenue Next 5Y9.58%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 25.27, VX1 can be considered very expensive at the moment.
Based on the Price/Earnings ratio, VX1 is valued a bit cheaper than the industry average as 76.32% of the companies are valued more expensively.
VX1's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 26.91.
Based on the Price/Forward Earnings ratio of 20.59, the valuation of VX1 can be described as rather expensive.
Based on the Price/Forward Earnings ratio, VX1 is valued cheaper than 82.89% of the companies in the same industry.
VX1's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 22.92.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.27 | ||
| Fwd PE | 20.59 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of VX1 indicates a somewhat cheap valuation: VX1 is cheaper than 73.68% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of VX1 indicates a somewhat cheap valuation: VX1 is cheaper than 77.63% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 31.35 | ||
| EV/EBITDA | 22.34 |
4.3 Compensation for Growth
VX1's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
VX1 has a very decent profitability rating, which may justify a higher PE ratio.
VX1's earnings are expected to grow with 328.73% in the coming years. This may justify a more expensive valuation.
PEG (NY)0
PEG (5Y)N/A
EPS Next 2Y746.68%
EPS Next 3Y328.73%
5. Dividend
5.1 Amount
VX1 does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:VX1 (10/23/2025, 7:00:00 PM)
369.15
-0.6 (-0.16%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners98.11%
Inst Owner ChangeN/A
Ins Owners0.13%
Ins Owner ChangeN/A
Market Cap94.65B
Revenue(TTM)11.42B
Net Income(TTM)3.64B
Analysts76.41
Price Target418.38 (13.34%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.87%
Min EPS beat(2)-7.2%
Max EPS beat(2)3.45%
EPS beat(4)2
Avg EPS beat(4)-0.78%
Min EPS beat(4)-7.2%
Max EPS beat(4)3.69%
EPS beat(8)5
Avg EPS beat(8)-64.35%
EPS beat(12)7
Avg EPS beat(12)-42%
EPS beat(16)10
Avg EPS beat(16)-30.64%
Revenue beat(2)1
Avg Revenue beat(2)-2.37%
Min Revenue beat(2)-4.8%
Max Revenue beat(2)0.06%
Revenue beat(4)2
Avg Revenue beat(4)-0.57%
Min Revenue beat(4)-4.8%
Max Revenue beat(4)2.68%
Revenue beat(8)3
Avg Revenue beat(8)-0.87%
Revenue beat(12)5
Avg Revenue beat(12)-0.45%
Revenue beat(16)8
Avg Revenue beat(16)0.05%
PT rev (1m)0.48%
PT rev (3m)-6.16%
EPS NQ rev (1m)-0.8%
EPS NQ rev (3m)-0.78%
EPS NY rev (1m)-0.15%
EPS NY rev (3m)0.56%
Revenue NQ rev (1m)0.03%
Revenue NQ rev (3m)0.42%
Revenue NY rev (1m)0.02%
Revenue NY rev (3m)0.45%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.27 | ||
| Fwd PE | 20.59 | ||
| P/S | 9.61 | ||
| P/FCF | 31.35 | ||
| P/OCF | 28.53 | ||
| P/B | 6.39 | ||
| P/tB | 7.01 | ||
| EV/EBITDA | 22.34 |
EPS(TTM)14.61
EY3.96%
EPS(NY)17.93
Fwd EY4.86%
FCF(TTM)11.77
FCFY3.19%
OCF(TTM)12.94
OCFY3.51%
SpS38.42
BVpS57.78
TBVpS52.66
PEG (NY)0
PEG (5Y)N/A
Graham Number137.82
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 15.13% | ||
| ROE | 21.18% | ||
| ROCE | 22.25% | ||
| ROIC | 15.66% | ||
| ROICexc | 23.06% | ||
| ROICexgc | 25.99% | ||
| OM | 38.77% | ||
| PM (TTM) | 31.86% | ||
| GM | 86.11% | ||
| FCFM | 30.65% |
ROA(3y)10.62%
ROA(5y)14.47%
ROE(3y)13.73%
ROE(5y)19.12%
ROIC(3y)17.53%
ROIC(5y)18.06%
ROICexc(3y)43.35%
ROICexc(5y)48.92%
ROICexgc(3y)62.02%
ROICexgc(5y)75.97%
ROCE(3y)24.89%
ROCE(5y)25.65%
ROICexgc growth 3Y-29.98%
ROICexgc growth 5Y-9.76%
ROICexc growth 3Y-22.64%
ROICexc growth 5Y-1.94%
OM growth 3Y2.79%
OM growth 5Y6.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y-0.17%
F-Score6
Asset Turnover0.48
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 173.52% | ||
| Cap/Sales | 3.04% | ||
| Interest Coverage | 260.41 | ||
| Cash Conversion | 83.13% | ||
| Profit Quality | 96.21% | ||
| Current Ratio | 2.52 | ||
| Quick Ratio | 2.16 | ||
| Altman-Z | N/A |
F-Score6
WACC9.37%
ROIC/WACC1.67
Cap/Depr(3y)171.61%
Cap/Depr(5y)187.83%
Cap/Sales(3y)3.11%
Cap/Sales(5y)3.32%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7966.67%
EPS 3Y-71.86%
EPS 5Y-44.14%
EPS Q2Q%135.23%
EPS Next Y6246.89%
EPS Next 2Y746.68%
EPS Next 3Y328.73%
EPS Next 5Y150.5%
Revenue 1Y (TTM)10.46%
Revenue growth 3Y13.31%
Revenue growth 5Y21.5%
Sales Q2Q%12.06%
Revenue Next Year10.06%
Revenue Next 2Y9.8%
Revenue Next 3Y9.54%
Revenue Next 5Y9.58%
EBIT growth 1Y4.24%
EBIT growth 3Y16.47%
EBIT growth 5Y29.7%
EBIT Next Year820.09%
EBIT Next 3Y129.43%
EBIT Next 5Y68.38%
FCF growth 1Y-9.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-5.45%
OCF growth 3YN/A
OCF growth 5YN/A
VERTEX PHARMACEUTICALS INC / VX1.DE FAQ
What is the ChartMill fundamental rating of VERTEX PHARMACEUTICALS INC (VX1.DE) stock?
ChartMill assigns a fundamental rating of 6 / 10 to VX1.DE.
What is the valuation status of VERTEX PHARMACEUTICALS INC (VX1.DE) stock?
ChartMill assigns a valuation rating of 6 / 10 to VERTEX PHARMACEUTICALS INC (VX1.DE). This can be considered as Fairly Valued.
What is the profitability of VX1 stock?
VERTEX PHARMACEUTICALS INC (VX1.DE) has a profitability rating of 7 / 10.
What are the PE and PB ratios of VERTEX PHARMACEUTICALS INC (VX1.DE) stock?
The Price/Earnings (PE) ratio for VERTEX PHARMACEUTICALS INC (VX1.DE) is 25.27 and the Price/Book (PB) ratio is 6.39.
What is the financial health of VERTEX PHARMACEUTICALS INC (VX1.DE) stock?
The financial health rating of VERTEX PHARMACEUTICALS INC (VX1.DE) is 7 / 10.